Analysts Set Endo International plc (NASDAQ:ENDP) Target Price at $4.79

Shares of Endo International plc (NASDAQ:ENDPGet Rating) (TSE:ENL) have been given an average recommendation of “Hold” by the nine analysts that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $4.79.

Several brokerages have commented on ENDP. BMO Capital Markets lowered their price objective on shares of Endo International from $8.00 to $4.00 in a report on Thursday, March 3rd. Barclays lowered shares of Endo International from an “equal weight” rating to an “underweight” rating and lowered their price objective for the stock from $5.00 to $2.00 in a report on Wednesday, March 2nd. Zacks Investment Research lowered shares of Endo International from a “hold” rating to a “strong sell” rating and set a $2.50 price objective for the company. in a report on Wednesday, February 9th. Piper Sandler decreased their target price on shares of Endo International from $5.00 to $3.00 and set a “neutral” rating for the company in a research note on Wednesday, March 2nd. Finally, Citigroup decreased their target price on shares of Endo International from $11.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, March 9th.

Institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA increased its position in shares of Endo International by 127.4% during the third quarter. BNP Paribas Arbitrage SA now owns 294,257 shares of the company’s stock valued at $953,000 after acquiring an additional 164,841 shares in the last quarter. LSV Asset Management increased its position in shares of Endo International by 430.5% during the third quarter. LSV Asset Management now owns 2,399,100 shares of the company’s stock valued at $7,773,000 after acquiring an additional 1,946,841 shares in the last quarter. Carolina Wealth Advisors LLC increased its position in shares of Endo International by 130.0% during the third quarter. Carolina Wealth Advisors LLC now owns 24,177 shares of the company’s stock valued at $78,000 after acquiring an additional 13,663 shares in the last quarter. Sterling Investment Advisors Ltd. bought a new stake in shares of Endo International during the third quarter valued at approximately $89,000. Finally, Russell Investments Group Ltd. increased its position in shares of Endo International by 12.6% during the third quarter. Russell Investments Group Ltd. now owns 470,795 shares of the company’s stock valued at $1,524,000 after acquiring an additional 52,535 shares in the last quarter. 73.62% of the stock is owned by institutional investors.

Shares of Endo International stock traded down $0.06 during trading on Monday, reaching $2.49. 4,257,877 shares of the stock were exchanged, compared to its average volume of 4,357,582. The stock’s fifty day moving average is $2.66 and its 200 day moving average is $3.80. The firm has a market cap of $581.84 million, a price-to-earnings ratio of -0.94 and a beta of 1.04. Endo International has a 1 year low of $1.94 and a 1 year high of $7.07.

Endo International (NASDAQ:ENDPGet Rating) (TSE:ENL) last issued its quarterly earnings data on Monday, February 28th. The company reported $0.84 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.70 by $0.14. Endo International had a negative net margin of 20.49% and a negative return on equity of 90.96%. The business had revenue of $789.43 million during the quarter, compared to analyst estimates of $733.97 million. During the same period last year, the business posted $0.75 earnings per share. Endo International’s quarterly revenue was up 3.8% compared to the same quarter last year. On average, analysts predict that Endo International will post 1.68 earnings per share for the current year.

About Endo International (Get Rating)

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology.

See Also

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.